Patents by Inventor Aaron Nakwon Chang

Aaron Nakwon Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE
    Publication number: 20240167026
    Abstract: Provided herein are compositions and methods of using prime editing systems comprising prime editors and prime editing guide RNAs for treatment of genetic disorders.
    Type: Application
    Filed: December 1, 2023
    Publication date: May 23, 2024
    Inventors: Jonathan M. LEVY, Wei Hsi YEH, Aaron Nakwon CHANG, John STILLER
  • USE OF P38 INHIBITORS TO REDUCE EXPRESSION OF DUX4
    Publication number: 20230257743
    Abstract: The present invention relates to compositions and methods of inhibiting p38 kinase to reduce gene and protein expression of DUX4 and downstream genes regulated by DUX4. The present invention further relates to methods for treating patients suffering from diseases associated with increased expression of DUX4 or expression of an aberrant form of DUX4, such as Facioscapulohumeral muscular dystrophy (FSHD).
    Type: Application
    Filed: September 20, 2022
    Publication date: August 17, 2023
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • Use of p38 inhibitors to reduce expression of DUX4
    Patent number: 11479770
    Abstract: The present invention relates to compositions and methods of inhibiting p38 kinase to reduce gene and protein expression of DUX4 and downstream genes regulated by DUX4. The present invention further relates to methods for treating patients suffering from diseases associated with increased expression of DUX4 or expression of an aberrant form of DUX4, such as Facioscapulohumeral muscular dystrophy (FSHD).
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: October 25, 2022
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD
    Publication number: 20220282254
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Application
    Filed: May 11, 2022
    Publication date: September 8, 2022
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, Iii, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD
    Publication number: 20220133704
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Application
    Filed: November 12, 2021
    Publication date: May 5, 2022
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
    Patent number: 11291659
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: April 5, 2022
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD
    Publication number: 20200383963
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, orZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Application
    Filed: January 21, 2020
    Publication date: December 10, 2020
    Inventors: Angela Marie CACACE, Luis Gustavo Alejandro ROJAS SOTO, Lorin A. THOMPSON, III, Owen Brendan WALLACE, Lucienne V. RONCO, Ning SHEN, Alan Scott ROBERTSON, Aaron Nakwon CHANG
  • USE OF P38 INHIBITORS TO REDUCE EXPRESSION OF DUX4
    Publication number: 20200332291
    Abstract: The present invention relates to compositions and methods of inhibiting p38 kinase to reduce gene and protein expression of DUX4 and downstream genes regulated by DUX4. The present invention further relates to methods for treating patients suffering from diseases associated with increased expression of DUX4 or expression of an aberrant form of DUX4, such as Facioscapulohumeral muscular dystrophy (FSHD).
    Type: Application
    Filed: October 5, 2018
    Publication date: October 22, 2020
    Inventors: Angela Marie CACACE, Luis Gustavo Alejandro ROJAS SOTO, Lorin A. THOMPSON, III, Owen Brendan WALLACE, Lucienne V. RONCO, Ning SHEN, Alan Scott ROBERTSON, Aaron Nakwon CHANG
  • P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
    Patent number: 10537560
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: January 21, 2020
    Assignee: Fulcrum Therapeutics. Inc.
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
    Patent number: 10342786
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: July 9, 2019
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang